Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography

被引:73
|
作者
Miles, KA [1 ]
Griffiths, MR
Keith, CJ
机构
[1] Univ Sussex, Brighton & Sussex Med Sch, Div Clin & Lab Sci, Brighton BN7 3PB, E Sussex, England
[2] Queensland Univ Technol, Gardens Point Brisbane, Brisbane, Qld, Australia
[3] Wesley Res Inst, Brisbane, Qld, Australia
关键词
non-small cell lung cancer; tumour blood flow; glucose metabolism; tumour size; F-18-FDG;
D O I
10.1007/s00259-005-1932-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: The purpose of this study was to undertake dual assessment of tumour blood flow and glucose metabolism in non-small cell lung cancer (NSCLC) using contrast-enhanced computed tomography (CE-CT) and F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in order to assess how the relationships between these parameters vary with tumour size and stage. Methods: Tumour blood flow and glucose metabolism were assessed in 18 NSCLCs using quantitative CE-CT and FDG-PET respectively. Contrast enhancement and FDG uptake were both normalised to injected dose and patient weight to yield correspondingly the standardised perfusion value (SPV) and standardised uptake value (SUV). Tumour area was measured from conventional CT images. Results: The ratio of SUV to SVP and the metabolic - flow difference ( SUV - SVP) correlated with tumour size ( r= 0.56, p= 0.015 and r= 0.60 and p= 0.008 respectively). A metabolic flow difference of greater than 4 was more common amongst tumours of stages III and IV ( odds ratio 10.5; 95% confidence limits 0.24 - 32.1). A significant correlation between SUV and SPV was found only for tumours smaller than 4.5 cm(2) ( r= 0.85, p= 0.03). Conclusion: Blood flow - metabolic relationships are not consistent in NSCLC but depend upon tumour size and stage. Quantitative CE-CT as an adjunct to an FDG study undertaken using integrated PET-CT offers an efficient way to augment the assessment of tumour biology with possible future application as part of clinical care.
引用
收藏
页码:22 / 28
页数:7
相关论文
共 50 条
  • [1] Blood flow–metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography
    K. A. Miles
    M. R. Griffiths
    C. J. Keith
    European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33 : 22 - 28
  • [2] Threshold modification for tumour imaging in non-small-cell lung cancer using positron emission tomography
    Yaremko, B
    Riauka, T
    Robinson, D
    Murray, B
    McEwan, A
    Roa, W
    NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (05) : 433 - 440
  • [3] Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer
    von Haag, DW
    Follette, DM
    Roberts, PF
    Shelton, D
    Segel, LD
    Taylor, TM
    JOURNAL OF SURGICAL RESEARCH, 2002, 103 (02) : 160 - 164
  • [4] Detection of nodal metastatic disease in patients with non-small cell lung cancer: comparison of positron emission tomography (PET), contrast-enhanced computed tomography (CT), and combined PET-CT
    Ventura, Elisa
    Islam, Tina
    Gee, Michael S.
    Mahmood, Umar
    Braschi, Marta
    Harisinghani, Mukesh G.
    CLINICAL IMAGING, 2010, 34 (01) : 20 - 28
  • [5] The value of contrast-enhanced computed tomography in evaluating patient response to Icotinib for non-small cell lung cancer
    Yu, Jinping
    Liu, Haixia
    Chen, Hong
    Ren, Shuhua
    BIOMEDICAL RESEARCH-INDIA, 2016, 27 (03): : 905 - 911
  • [6] Presurgical staging of non-small cell lung cancer - Positron emission tomography, integrated positron emission tomography/CT, and software image fusion
    Halpern, BS
    Schiepers, C
    Weber, WA
    Crawford, TL
    Fueger, BJ
    Phelps, ME
    Czernin, J
    CHEST, 2005, 128 (04) : 2289 - 2297
  • [7] Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: A review
    Pillot, Giancarlo
    Siegel, Barry A.
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (02) : 152 - 159
  • [8] Positron Emission Tomography (PET) in the Evaluation of Response to Therapy in Non-Small Cell Lung Cancer
    Delgado-Bolton, Roberto C.
    Carreras Delgado, Jose Luis
    CURRENT CANCER THERAPY REVIEWS, 2009, 5 (01) : 20 - 27
  • [9] Staging of the mediastinum: Value of positron emission tomography imaging in non-small cell lung cancer
    Bury, T
    Paulus, P
    Dowlati, A
    Corhay, JL
    Weber, T
    Ghaye, B
    Schoffers, J
    Limet, R
    Albert, A
    Rigo, P
    Radermecker, M
    EUROPEAN RESPIRATORY JOURNAL, 1996, 9 (12) : 2560 - 2564
  • [10] Positron emission tomography for target volume definition in the treatment of non-small cell lung cancer
    Lavrenkov, K
    Partridge, M
    Cook, G
    Brada, M
    RADIOTHERAPY AND ONCOLOGY, 2005, 77 (01) : 1 - 4